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Abstract
Introduction: Surgery remains the most effective treatment for primary hyperparathyroidism (PHPT). Minimally invasive radioguided 
parathyroidectomy (MIRP) is a common technique for detecting and excising abnormal parathyroid glands. The aim of this study was to 
compare injections of low-dose and high-dose (99m) Tc methoxy isobutyl isonitrile (MIBI) for intraoperative localisation of parathyroid 
adenomas by means of a gamma probe in patients with primary hyperparathyroidism (PHPT).
Material and methods: Thirty patients with PHPT and a preoperative diagnosis of parathyroid adenoma were enrolled between 2010 
and 2012. They were considered as Group B and underwent MIRP using 5 mCi Tc-99m MIBI, and their perioperative data were compared 
with twenty patients treated with conventional 20 mCi Tc-99m MIBI previously (Group A).
Results: Group A was made up of 20 patients (mean age, 41.55 years; 14 women and 6 men), and group B included 30 patients (mean age, 
40.43 years; 19 women and 11 men). The mean serum parathyroid hormone (PTH) and calcium values were recorded pre- and postop-
eratively. The mean follow-up period for the patients in the two groups was 18.4 and 16.5 months, respectively. Pre-operative evaluation 
demonstrated that the groups were statistically similar. Intraoperative data and success rate of surgery showed no difference between 
the two groups. No significant complication was detected after surgeries and no recurrence happened in either of the two groups during 
the follow-up period.
Conclusions: A new protocol of MIRP using low doses of Tc-99m-MIBI resulted in an excellent success rate. Comparing results of the 
study, we conclude that low-dose Tc-99m-MIBI may be preferred for identification of parathyroid adenomas intraoperatively by means 
of a gamma probe in PHPT patients because it appears to be as effective as high-dose Tc-99m-MIBI. (Endokrynol Pol 2017; 68 (4): 398–401)
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Streszczenie
Wstęp: Najbardziej skutecznym leczeniem pierwotnej nadczynności przytarczyc (PHPT, primary hyperparathyroidism) nadal pozostaje zabieg 
chirurgiczny. Minimalnie inwazyjna paratyroidektomia z lokalizacją radioizotopową (MIRP, minimally invasive radioguided parathyroidectomy) 
jest techniką często stosowaną do wykrywania i wycinania nieprawidłowych przytarczyc. Badanie przeprowadzono w celu porównania 
małej i dużej dawki (99m) Tc metoksy-izobutylu-izonitrylu (MIBI) podawanych w celu śródoperacyjnej lokalizacji gruczolaków przytarczyc 
za pomocą sondy gamma u chorych z pierwotną nadczynnością przytarczyc (PHPT, primary hyperparathyroidism).
Materiał i metody: W latach 2010–2012 do badania włączono 30 chorych z PHPT i przedoperacyjnym rozpoznaniem gruczolaka przy-
tarczyc. W tej grupie chorych określonej jako grupa B wykonano MIRP po podaniu 5 mCi Tc-99m MIBI, a dane okołooperacyjne tych 
chorych porównano z danymi 20 pacjentów, u których zastosowano konwencjonalną dawkę 20 mCi Tc-99m MIBI (grupa A).
Wyniki: Grupa A składała się z 20 chorych (średnia wieku 41,55 r.; 14 kobiet i 6 mężczyzn), a grupę B tworzyło 30 chorych (średnia wieku 
40,43 r.; 19 kobiet i 11 mężczyzn). Zmierzono przed- i pooperacyjne stężenia w surowicy parathormonu (PTH, pathyroid hormone) i wapnia. 
Średni okres obserwacji chorych w grupach A i B wynosił odpowiednio 18,4 i 16,5 miesiąca. Ocena przedoperacyjna wykazała, że grupy 
nie różniły się statystycznie między sobą. Również dane śródoperacyjne odsetek zabiegów zakończonych powodzeniem były podobne 
w obu grupach. W żadnej z grup nie stwierdzono istotnych powikłań pozabiegowych ani nawrotu w okresie obserwacji.
Wnioski: Nowy protokół MIRP z użyciem małych dawek Tc-99m-MIBI wiązał się z bardzo wysokim odsetkiem pomyślnych zabiegów. 
Porównanie wyników uzyskanych w badaniu pozwala sformułować wniosek, że do śródoperacyjnego identyfikowania za pomocą sondy 
gamma gruczolaków nadnercza u chorych z PHPT mogą być preferowane małe dawki Tc-99m-MIBI, ponieważ są równie skuteczne jak 
duże dawki Tc-99m-MIBI. (Endokrynol Pol 2017; 68 (4): 398–401)
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Introduction
Hyperparathyroidism is an endocrine disorder charac-
terised by excessive secretion of parathyroid hormone 
(PTH), which can cause various symptoms and severe 
morbidities. Primary hyperparathyroidism (PHPT) is 
due to excessive secretion of parathyroid hormone by 
one or more parathyroid glands [1].
PHPT is a common clinical endocrine disorder in 
many countries. The prevalence of PHPT has recently 
increased compared to the past, maybe as a result of 
improved biochemical tests [2]. Almost 1 out of every 
2000 men and 1 out of every 500 women are affected 
by this disease each year. In more than 80% of PHPT 
patients, a single parathyroid adenoma is detected. The 
second common cause of PHPT is parathyroid hyper-
plasia (15–20% of all patients). Multiple parathyroid 
adenomas and parathyroid carcinomas are other less 
common causes [3].
The only curative treatment for hyperparathy-
roidism is surgery. The first successful parathyroid-
ectomy was performed in 1925, with bilateral neck 
exploration, and since then this has remained the stand-
ard treatment of PHPT [4, 5]. Although bilateral neck 
exploration is still the traditional surgical approach, 
selective parathyroidectomy can also be performed us-
ing minimally invasive, video-assisted, endoscopic, or 
radio-guided techniques [6–7]. With the introduction of 
Tc-99m-sestamibi scintigraphy to identify and locate the 
parathyroid adenoma preoperatively, the era of mini-
mally invasive radioguided parathyroidectomy (MIRP) 
began [8]. MIRP is gradually being replaced traditional 
bilateral neck exploration as the procedure of choice in 
many institutions, with comparable results [9]. MIRP is 
a less invasive surgical approach to hyperparathy-
roidism, which could decrease the time, hospital stay, 
and cost of parathyroid surgery [10–12].
The usual technique for MIRP is intravenous injec-
tion of 20–25 mCi Tc-99m-MIBI 2–4 hours before the 
operation and use of an intraoperative gamma probe 
for localisation of the abnormal parathyroid glands. This 
protocol offers the advantage of performing parathy-
roid scintigraphy and surgery on the same day [13–15]. 
Later, Murphy and Norman proposed the so-called 
“20% rule” that has been reported to yield 100% accu-
racy in distinguishing solitary parathyroid adenomas 
from hyperplasia during MIRP [16].
One of the main concerns of any radioguided sur-
gery is the radiation exposure to the patient and the 
surgical staff. The patient’s exposure is limited to one 
operation. But the surgeon and the operating room staff 
are repeatedly exposed to radiation during multiple 
procedures [17]. Usually there are a large number of 
different sources of radiation in these areas; however, 
during MIRP there is a unique source of radiation: 
the patient [18]. A large number of studies have been 
conducted to reduce the dose of radiotracers during 
surgeries [19–23].
In the current study, we used low-dose (5 mCi) 
Tc-99m-MIBI for MIRP with a separate day protocol 
and compared the results with standard high dose 
(20 mCi) regarding demographics, clinical presenta-
tions, and surgical outcomes.
Material and methods
All patients with primary hyperthyroidism were includ-
ed in the study with informed consent if meeting the 
following criteria: a) evidence of solitary parathyroid 
adenoma on the pre-operative Tc-99m-MIBI scintigra-
phy, b) no thyroid nodule on palpation or preoperative 
ultrasound evaluation, c) no history of multiple endo-
crine neoplasia (MEN) or familial hyperparathyroidism, 
d) no history of previous neck surgery or radiation, and 
e) follow-up for at least six months.
From March 2007 to December 2009 (Group A), the 
patients received 20 mCi Tc-99m-MIBI intravenously 
three hours before surgery. All patients underwent gen-
eral anaesthesia for surgical removal of abnormal para-
thyroid glands. A hand-held gamma probe (Europrobe, 
GMS, France) was used for mapping the radioactivity 
and localisation of the abnormal gland. After spotting 
the hottest point in the neck (which was correlated with 
the pre-operative Tc-99m-MIBI scintigraphy), a small 
(2–3 cm) incision was made over the point, and under 
the guide of the probe the hot parathyroid tissues were 
removed. The ex vivo radioactivity from the excised 
tissue was recorded and the equivalent radioactivity 
from the background surgical field was measured (in 
counts per second of gamma radiation). The procedure 
was considered successful if radioactivity in the excised 
tissue was at least 20% of the background activity and 
it was morphologically consistent with the parathyroid 
gland. No drains were used. The operation time was re-
corded from incision to complete closure in all patients. 
The serum calcium and serum PTH were measured the 
next day after surgery and before discharge.
Intra-operative PTH assay was not used. Special care 
was taken to preserve the recurrent laryngeal nerve. 
From January 2010 to October 2012 (Group B), we 
changed the dose of Tc-99m-MIBI to 5 mCi. The remain-
ing aspects of surgical treatment protocol remained 
the same.
We compared the success of surgery (based on 
pathology results, decrease in PTH and serum calcium 
levels post-operatively), rate of complications, ex vivo 
count rates of the abnormal glands, and background and 
surgical parameters between group A and B patients. 
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All data were analysed using SPSS 16, and the 
results were expressed as mean ± 1SD. Comparison 
of the data was performed by Mann Whitney-U and 
Chi-square tests. Results with p values lower than 0.05 
were considered significant.
Results
Overall, 50 patients included in the study. Twenty 
patients received the standard high dose (20 mCi) of 
Tc-99m-MIBI. In this group (group A), the 20% rule 
could be achieved in 19 patients, and only one patient 
underwent bilateral neck dissection. Thirty patients 
received low-dose (5 mCi) Tc-99m-MIBI. In this group 
(group B), the 20% rule was achieved in all patients, and 
no bilateral neck dissection was performed.
The mean age was 41.55 years (range, 26–68 years) 
and 40.43 years (range, 24–61 years) in groups A and 
group B, respectively. No significant difference was de-
tected in the female: male ratio between the two groups. 
Traditional bilateral neck exploration via a transverse 
neck incision was performed in only one case in group 
A and in none of the cases in group B (Table I). 
The mean operative time was 36.65 minutes (range, 
20–54 minutes) in group A and 35.46 minutes (range, 
18–75 minutes) in group B, which was calculated after 
excluding the only case with conversion to bilateral 
neck exploration for group A. The length of the inci-
sion in two groups was measured with no statistically 
significant deference. The size of the removed parathy-
roid adenomas was similar in Group A and Group B 
(22.25 ± 6.5 mm vs. 25.84 ± 5.12 mm, respectively) 
(Table I).
Using a hand-held gamma probe, counts per seconds 
were obtained from ex vivo excised gland and the back-
ground field where the gland was removed (Table II).
Serum calcium and serum PTH were measured before 
and after operation. The results are shown in Table III. 
In all patients in the two groups there was more than 
a 50% decrease in PTH levels in the first postoperative 
day with respect to preoperative serum PTH levels. The 
postoperative first day calcium levels in all patients, in 
both groups, reduced to normal range. 
There were no recurrent laryngeal nerve injuries 
and no wound complications such as infection or 
hematoma in two groups. No patient was affected 
by permanent hypoparathyroidism, although a few 
cases of transient hypocalcaemia were observed in 
both groups with no statistically significant difference 
(p value = 0.85). All of them were treated accordingly 
with excellent outcomes.
MIRP was successful in all patients of both groups 
based on pathology and laboratory results including 
serum PTH and serum calcium, postoperatively. 
No recurrences happened and all patients remained 
free of hypercalcaemia during a follow-up of 18.4 
months (range, 11–40 months) in group A and 16.5 
months (range, 10–36 months) in group B. 
Discussion
Most patients presenting with PHPT have a single 
adenoma, and surgical excision has remained the 
standard of care, with a very low rate of complications 
and excellent results [4, 24]. Patients enjoy a very good 
quality of life postoperatively, and a quick return to 
age- and sex-matched life span is expected in almost 
all of them.
Table I. Perioperative characteristics of the patients
Tabela I. Charakterystyka okresu okołooperacyjnego 
pacjentów
Group A 
N = 20
Group B 
N = 30
p-value
Age (year) 41.55 ± 10.25 40.43 ± 12.34 0.85
Gender (Female:Male) 14:6 19:11 0.48
Size of Adenoma [mm] 22.25 ± 6.5
(range, 11–36)
25.84 ± 5.12
(range, 10–45)
0.59
Mean Operation time 
[min]
36.65 ± 7.5 
(range, 20–54)
35.46 ± 8.5 
(range, 18–75)
0.84
Mean Length of 
incision [mm]
32.45 ± 1.5 
(range, 30–40)
34 ± 2.4 
(range, 30–45)
0.54
Conversion to 
conventional neck 
exploration
1 0
RLN injury 0 0
Permanent 
hypoparathyroidism
0 0
Transient hypocalcemia 3 5 0.85
Mean follow up 
(months)
18.4 ± 5.2 
(11–40)
16.5 ± 4.8 
(10–36)
0.74
Table II. Intraoperative radioactivity findings
Tabela II. Śródoperacyjne wyniki dotyczące promieniowania
Group A 
N = 20
Group B 
N = 30
p-value
Ex vivo parathyroid 
adenoma counts
(counts/seconds)
436 ± 212 396 ± 184 0.46
Background tissue 
counts
(counts/seconds)
240 ± 94 238 ± 84 0.40
Ratio of adenoma to 
background counts (%)
178.4 ± 52 1.65 ± 36 0.55
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Table III. Preoperative and postoperative serum PTH and calcium
Tabela III. Przedoperacyjne i pooperacyjne stężenie PTH i wapnia
Group A 
N = 20
Group B 
N = 30
Preoperative Postoperative Preoperative Postoperative
Total serum 
calcium [mg/dl]
11.6 ± 0.6 9.8 ± 0.8 0.02 11.4 ± 0.5 9.2 ± 0.6 0.01
Serum parathyroid 
hormone [pg/ml]
945 ± 364 61 ± 36 0.001 894 ± 312 48 ± 28 0.001
There are different protocols for a surgical ap-
proach to PHPT. Norman’s protocol consists of three 
main steps. First, the patient is injected with 20 mCi of 
Tc-99-MIBI in a nuclear medicine facility. Second, a dual 
phase scintigraphy technique is used to perform preop-
erative imaging. Finally, the patient is operated using 
a gamma-probe in about three hours. Our protocol 
presents some differences, including preoperative and 
surgery in separate days and injection of a four-times 
lower dose of Tc-99m-MIBI. Despite these differences, 
the results were comparable and promising. Besides, 
the so-called “20% rule” was achieved in all patients 
who had received a lower dose Tc-99-MIBI.
Based on the data of the present study, it can be 
concluded that a Tc-99 MIBI dose as low as 5 mCi ap-
pears to be adequate to perform MIRP with similar 
results in comparison to the conventional dose of 
20 mCi. There is also a valuable advantage of decreased 
radiation exposure to the surgical staff and patient due 
to this lowered dose of Tc-99 MIBI.
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